TACSTD2 and prostate carcinoma: Safety assessments in rats indicated that SHR-A1921 had an acceptable safety profile.<h4>Conclusion</h4>SHR-A1921 is a promising Trop-2-targeted ADC that leverages innovative technology to deliver potent antitumor activity against Trop-2-expressing prostate cancer cells, with an acceptable safety profile observed in preclinical studies.